David S. Geldmacher, MD, FACP is Co-Chair of the ACTC Site Metrics and Study Budgets Committee (SBSMC) and a Site Member PI on the ACTC Steering Committee. He holds the Warren Family Endowed Chair in Neurology. He is Director of the Division of Memory Disorders and Behavioral Neurology at the University of Alabama at Birmingham. He serves as Medical Director for Neurology at the University of Alabama (UAB) Hospital.

His research has centered on testing new dementia treatments and understanding the meaningfulness of treatment outcomes for affected people and their families. His other research interests include complex visual processing in aging and neurological conditions.

Dr. Geldmacher is the author of Contemporary Diagnosis and Management of Alzheimer’s Dementia, and has published over 100 research articles, chapters, abstracts and reviews.

He is a Fellow of both the American College of Physicians and the American Neurological Association. He has been elected as a member of the Alpha Omega Alpha medical honor society and has been listed in Best Doctors in America since 1998.

Dr. Geldmacher graduated magna cum laude from the University of Rochester (New York) with his B.A. in Biology and Psychology. He obtained his M.D (with Certificate in Academic Research) from the State University of New York – Health Science Center at Syracuse. He trained in Neurology at Case Western Reserve University and completed a postdoctoral fellowship in Behavioral Neurology at the University of Florida.

Dr. Gad Marshall is board certified in Neurology, and is the Associate Medical Director of Clinical Trials at the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital; Associate Neurologist at Brigham and Women’s Hospital; Assistant in Neurology at Massachusetts General Hospital; and Associate Professor of Neurology at Harvard Medical School.

Dr. Marshall has served as site principal investigator for 13 Alzheimer’s disease clinical trials and 4 multicenter observational imaging biomarker studies, including currently the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 3, DoD-ADNI, and the Trial-Ready Cohort for Preclinical/Prodromal AD (TRC-PAD). He is the Brigham and Women’s Hospital Site Principal investigator, Steering Committee Member, and Chair of the Publications Committee for the Alzheimer’s Clinical Trial Consortium (ACTC).

His research has focused on clinical correlates of instrumental activities of daily living and neuropsychiatric symptoms with amyloid, tau, and FDG PET, structural and resting-state functional MRI, and CSF biomarkers across the early Alzheimer’s disease spectrum.

Christopher van Dyck serves as Co-Chair for the Protocol Evaluation Committee (PEC) and a member of the Executive Committee for the ACTC. He is also Professor of Psychiatry, Neurology, and Neuroscience and Director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine.

Dr. van Dyck is a graduate of Yale College and Northwestern University Medical School. He completed his residency in psychiatry, fellowship in geriatric psychiatry, and research fellowship in neuroimaging before joining the faculty at Yale.

Dr. van Dyck is a recognized leader in the neuroimaging and therapeutics of Alzheimer’s disease and healthy aging. He is also Principal Investigator on grants from the National Institutes of Health, the pharmaceutical industry, and a number of private foundations and has authored more than 200 papers and reviews. Finally, Dr. van Dyck is extremely committed to advancing the cause of Alzheimer’s patients and their families on the local and national level. As Chairman of the Medical Scientific Advisory Committee for the Connecticut Chapter of the Alzheimer’s Association, he is intimately involved with local program development, advocacy, and education. He received the Alzheimer’s Association’s “Compassion and Cure” Award for 2005 and “Leader in Advancing Research” Award for 2017.

Bruno Vellas serves as Co-Chair for the ACTC Non-Pharmacological Interventions Committee. Dr. Vellas is the chair of the Gérontopôle & Department of Geriatric Internal Medicine at the Toulouse University Hospital and is member of INSERM UMR 1027. He studied medicine in Toulouse and received the degree of Doctor of Medicine in 1987 and a PhD in Pysiopathology in 1990. He had a doctoral training in nutrition and aging at the University of New Mexico, USA, Clinical Nutrition Lab, School of Medicine from 1987 to 1988. His main interests are: development of aging and geriatric clinical research and care. His research and care has been supported by several European, national and international research grants. He is the founder of the Gérontopôle to develop innovation and research for older adults. He is the author and co-author of more than 800 publications in peer review journals since 1987, Index H: 75. He serves as editor, editorial committee member and reviewer of several major journals. He is adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA and is member of the scientific advisory board of several major scientific institutions in France, EU, Japan and the US. Since 2016, he is titular member of the French National Academy of Medicine, Officier de la Légion d’Honneur, and was recipient of the Palmes Académiques in 2016. He is the past president of the IAGG (International Association of Gerontology and Geriatrics) a NGO with a seat at the United Nations, and the founder of the EADC (European Alzheimer’s Disease Consortium), the CTAD (Clinical Trial in Alzheimer’s Disease conference) and the ICFSR (International Conference for Frailty and Sarcopenia Research). He is the chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017. Lastly, Bruno VELLAS is Principal Investigator of the INSPIRE program in the field of Gerosciences.